Therapy (TB)

IL-12 May Benefit Immunosuppressed MDR-TB Patients

Published in TB and Outbreaks Week, February 24th, 1997

Patients with multidrug-resistant tuberculosis (TB) who have CD4⁺ T cell counts below 500 have impaired interferon-gamma and interleukin 2 responses and might benefit from adjunctive interleukin-12 therapy, according to a report from the U.S. National Institute of Allergy and Infectious Diseases.

"(Our) study confirms previous work showing that interleukin-12 (IL-12) can enhance interferon gamma (IFN-gamma) production in an antigen-specific manner," researcher John F. McDyer and colleagues wrote ("Patients with MDR-TB with Low CD4⁺ T Cell Counts Have Impaired Th1 Responses," The Journal of Immunology, January 1997;158(1):492-500).

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (1997-02-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry